Get the Daily Brief
Latest Biotech News
Court Invalidates Scale Patent in Parse Biosciences Dispute
A U.S. district court held that claims of US Patent No. 11,634,752—owned by Scale Biosciences and asserted against Parse Biosciences—are invalid for lack of written description and enablement. The...
Catalent Taps Lisata’s Certepetide for ADC Payload Work – $10M Pact
Catalent entered a collaboration with Lisata to evaluate certepetide and analogs as payloads for antibody‑drug conjugates (ADCs), in a pact that could deliver up to $10 million in study initiation...
Ex‑Moderna Leaders Close $325M Ascenta Fund to Back Platform Biotechs
Former Moderna executives Evan Rachlin and Lorence Kim closed Ascenta Capital’s inaugural fund at $325 million to invest in platform‑stage biotechs. The firm targets indication‑agnostic,...
Novo buys Akero: $4.7B bet on late‑stage MASH drug
Novo Nordisk agreed to acquire Akero Therapeutics for $4.7 billion upfront to add efruxifermin, an FGF21‑mimetic candidate in late‑stage testing for metabolic dysfunction‑associated...
Tempus lands $60.5M ARPA‑H contract: AI tests for precision cancer
Tempus AI secured a $60.5 million, five‑year contract from ARPA‑H to provide testing and contract research support for the ADAPT precision cancer therapy program. Under the agreement Tempus will...
FDA clears Jascayd: first new IPF pill in over a decade
The U.S. Food and Drug Administration approved Boehringer Ingelheim’s Jascayd (nerandomilast), a preferential PDE4B inhibitor, for idiopathic pulmonary fibrosis (IPF), marking the first new FDA...
Judge invalidates Scale Bio patent: win for Parse in single‑cell fight
A U.S. district court judge found key claims of a Scale Biosciences patent invalid for lack of written description and enablement, handing Parse Biosciences a courtroom victory in a patent...
Mammoth reveals monkey data: advancing in‑vivo triglyceride gene‑editing trial
Mammoth Biosciences disclosed non‑human primate data from its lead program showing durable triglyceride lowering after a single in‑vivo gene editing intervention, and announced plans to move the...
Ex‑Moderna leaders raise $325M: Ascenta Capital launches big biotech fund
Two former Moderna executives have closed Ascenta Capital’s inaugural biotech fund at $325 million, backing early‑stage life science investments. The fund, formed in 2023 and now publicly...
Nilo launches with $101M: brain‑to‑immune startup targets systemic inflammation
Nilo Therapeutics launched with a $101 million Series A to advance preclinical programs that target neural circuits controlling systemic immunity. The company, founded by academic neuro‑immunology...
Chiesi takes Arbor program: $2.1B option to build gene‑editing rare liver pipeline
Chiesi Group entered an exclusive collaboration and license with Arbor Biotechnologies to develop Arbor’s lead gene editing candidate ABO‑101 for primary hyperoxaluria type 1 (PH1) and to access...
Tessera awarded ARPA‑H funds: $41.3M to advance in‑vivo CAR‑T engineering
Tessera Therapeutics received up to $41.3 million from ARPA‑H to support its EMBODY program, which aims to develop in‑vivo CAR‑T approaches that engineer immune cells directly in patients. The...
Sanofi, Orano Med report phase‑2 win: AlphaMedix meets response endpoint in GEP‑NETs
Sanofi and partner Orano Med reported positive Phase 2 results for AlphaMedix, a targeted alpha‑emitting radiopharmaceutical in gastroenteropancreatic neuroendocrine tumors (GEP‑NETs). In a...
Novo Nordisk buys Akero for fatty-liver drug – $4.7B upfront
Novo Nordisk agreed to acquire Akero Therapeutics for $4.7 billion upfront to secure a late-stage therapy for metabolic dysfunction–associated steatohepatitis (MASH). The deal, disclosed by Novo,...
AstraZeneca bets $555M on Algen’s CRISPR-AI platform for target discovery
AstraZeneca struck a multi-year research partnership valued at up to $555 million with Algen Biotechnologies to use Algen’s AlgenBrain platform — a CRISPR-enabled, AI-integrated functional...
Mammoth Biosciences shows monkey proof for in vivo triglyceride gene edit ... first human trial planned
Mammoth Biosciences disclosed non-human primate data for its lead in vivo gene editing program that aims to permanently lower triglycerides. The company presented monkey efficacy and safety...
Chiesi and Arbor ink up-to-$2.1B gene-editing pact for rare liver diseases
Chiesi Group entered an exclusive collaboration and license with Arbor Biotechnologies to develop and commercialize Arbor’s ABO-101, a liver-directed gene editing candidate for primary...
Ono’s EP4 antagonist with Opdivo meets primary PFS endpoint in phase 2 gastric cancer
Ono Pharmaceutical reported that ONO-4578, an EP4 receptor antagonist developed with Bristol Myers Squibb outside certain territories, hit the progression‑free survival (PFS) primary endpoint in a...
Sanofi’s AlphaMedix radiopharmaceutical hits phase 2 response goals in neuroendocrine tumors
Sanofi disclosed positive Phase 2 results for AlphaMedix, an alpha-emitting targeted radioligand therapy (developed with Orano Med/RadioMedix) for gastroenteropancreatic neuroendocrine tumors...
FDA amends Xeloda label: pre‑treatment DPYD genetic testing now recommended
The U.S. Food and Drug Administration updated the boxed warning for Genentech’s capecitabine (Xeloda) to explicitly recommend pre‑treatment DPYD genetic testing to identify patients with...